US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
NZ511442A
(en)
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
HU230828B1
(en)
|
1999-10-29 |
2018-08-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6344215B1
(en)
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
WO2002036099A1
(en)
|
2000-10-30 |
2002-05-10 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US20040115261A1
(en)
*
|
2001-04-05 |
2004-06-17 |
Ashley Robert A. |
Controlled delivery of tetracycline compounds and tetracycline derivatives
|
US20020187192A1
(en)
*
|
2001-04-30 |
2002-12-12 |
Yatindra Joshi |
Pharmaceutical composition which reduces or eliminates drug abuse potential
|
US20030068375A1
(en)
*
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
US7988993B2
(en)
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
JP4865330B2
(ja)
|
2002-12-13 |
2012-02-01 |
デュレクト コーポレーション |
経口ドラッグデリバリーシステム
|
US8367111B2
(en)
*
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
EP2204168B1
(en)
|
2003-04-07 |
2015-01-14 |
Supernus Pharmaceuticals, Inc. |
Once daily formulations of tetracyclines
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
AR046410A1
(es)
*
|
2003-09-18 |
2005-12-07 |
Cephalon Inc |
Composiciones farmaceuticas para la liberacion modificada de modafinilo
|
US7387793B2
(en)
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
ES2261006B1
(es)
|
2004-06-10 |
2007-11-01 |
Laboratorios Rubio, S.A. |
Pellet multicapa de liberacion controlada de metilfenidato.
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
CA2476101A1
(en)
*
|
2004-08-12 |
2006-02-12 |
Bernard Charles Sherman |
Extended-release capsules comprising venlafaxine hydrochloride
|
US8747895B2
(en)
*
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
AU2005299490C1
(en)
|
2004-10-21 |
2012-01-19 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
US20060127421A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Celgene Corporation |
Treatment using D-threo methylphenidate
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
KR20080007586A
(ko)
*
|
2005-04-12 |
2008-01-22 |
엘란 파마 인터내셔널 리미티드 |
세균감염증의 치료를 위한 세팔로스포린 함유 조절 방출조성물
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
CA2645855C
(en)
|
2006-03-16 |
2015-02-03 |
Tris Pharma, Inc. |
Modified release formulations containing drug-ion exchange resin complexes
|
US20190083399A9
(en)
*
|
2006-04-03 |
2019-03-21 |
Isa Odidi |
Drug delivery composition
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
EP1973528B1
(en)
|
2006-11-17 |
2012-11-07 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
US20080131501A1
(en)
*
|
2006-12-04 |
2008-06-05 |
Supernus Pharmaceuticals, Inc. |
Enhanced immediate release formulations of topiramate
|
WO2009088414A2
(en)
|
2007-12-06 |
2009-07-16 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
RU2493830C2
(ru)
|
2008-01-25 |
2013-09-27 |
Грюненталь Гмбх |
Лекарственная форма
|
TW200940110A
(en)
*
|
2008-02-22 |
2009-10-01 |
Astrazeneca Ab |
Pharmaceutical formulation comprising oxabispidines
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010053306A2
(ko)
*
|
2008-11-07 |
2010-05-14 |
주식회사 삼양사 |
메칠페니데이트의 방출 제어용 약제학적 조성물
|
JP5783908B2
(ja)
|
2008-12-19 |
2015-09-24 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
攻撃性を治療する方法
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
PL2456427T3
(pl)
|
2009-07-22 |
2015-07-31 |
Gruenenthal Gmbh |
Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
|
EP2997965B1
(en)
|
2009-07-22 |
2019-01-02 |
Grünenthal GmbH |
Tamper-resistant dosage form for oxidation-sensitive opioids
|
WO2011020032A2
(en)
*
|
2009-08-13 |
2011-02-17 |
Kudco Ireland, Ltd. |
Pharmaceutical dosage form
|
CN108159019A
(zh)
|
2009-12-02 |
2018-06-15 |
阿黛尔药物有限公司 |
非索非那定微胶囊及含有非索非那定微胶囊的组合物
|
AR079862A1
(es)
*
|
2010-01-08 |
2012-02-22 |
Eurand Inc |
Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
|
JP6063377B2
(ja)
|
2010-03-31 |
2017-01-18 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
Cns化合物の安定化製剤
|
TWI516286B
(zh)
|
2010-09-02 |
2016-01-11 |
歌林達股份有限公司 |
含陰離子聚合物之抗破碎劑型
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
CN101933913A
(zh)
*
|
2010-09-16 |
2011-01-05 |
孙卫东 |
一种盐酸右哌甲酯双释放制剂及其制备方法
|
US8287903B2
(en)
*
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
SG193587A1
(en)
*
|
2011-03-23 |
2013-10-30 |
Ironshore Pharmaceuticals & Dev Inc |
Methods and compositions for treatment of attention deficit disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
WO2013003622A1
(en)
|
2011-06-28 |
2013-01-03 |
Neos Therapeutics, Lp |
Dosage forms for oral administration and methods of treatment using the same
|
LT2736495T
(lt)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
|
BR112014001091A2
(pt)
|
2011-07-29 |
2017-02-14 |
Gruenenthal Gmbh |
comprimido resistente à adulteração que fornece liberação imediata do fármaco
|
FR2983197B1
(fr)
*
|
2011-11-29 |
2014-07-25 |
Assist Publ Hopitaux De Paris |
Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
|
BR112014019988A8
(pt)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
|
AR090695A1
(es)
|
2012-04-18 |
2014-12-03 |
Gruenenthal Gmbh |
Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
BR112015003120B1
(pt)
|
2012-08-15 |
2022-08-09 |
Tris Pharma , Inc |
Tablete mastigável de liberação estendida de metilfenidato e seu uso
|
EP2983468A4
(en)
|
2013-03-15 |
2016-09-07 |
Durect Corp |
COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
|
WO2014174388A1
(en)
|
2013-03-29 |
2014-10-30 |
Wockhardt Limited |
Modified release pharmaceutical compositions of methylphenidate or salts thereof
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
|
CA2907950A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
MX368846B
(es)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
|
CA2931553C
(en)
|
2013-11-26 |
2022-01-18 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(en)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US20170296476A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Grünenthal GmbH |
Modified release abuse deterrent dosage forms
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
KR20240033130A
(ko)
|
2016-11-01 |
2024-03-12 |
네오스 테라퓨틱스, 엘피 |
Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여
|
EP3372225A1
(en)
*
|
2017-03-09 |
2018-09-12 |
Develco Pharma Schweiz AG |
Novel dosage form
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
CN111465390A
(zh)
*
|
2017-10-13 |
2020-07-28 |
格吕伦塔尔有限公司 |
调释防滥用剂型
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|